Characteristics of patients by FCGR3A-158V/F polymorphism
| . | FCGR3A-158VV . | FCGR3A-158VF . | FCGR3A-158FF . | P* . |
|---|---|---|---|---|
| No. (%) | 10 (20) | 22 (45) | 17 (35) | |
| Sex | ||||
| M | 3 | 12 | 10 | NS |
| F | 7 | 10 | 7 | |
| Disease stage | ||||
| II-III | 3 | 6 | 6 | NS |
| IV | 7 | 16 | 11 | |
| Bone marrow involvement | ||||
| Yes | 7 | 16 | 9 | NS |
| No | 3 | 6 | 8 | |
| Extranodal sites involved | ||||
| Less than 2 | 8 | 20 | 13 | NS |
| 2 or more | 2 | 2 | 4 | |
| BCL2-JHrearrangement in peripheral blood | 8 | 12 | 11 | NS |
| BCL2-JH rearrangement in bone marrow | 7 | 12 | 11 | NS |
| . | FCGR3A-158VV . | FCGR3A-158VF . | FCGR3A-158FF . | P* . |
|---|---|---|---|---|
| No. (%) | 10 (20) | 22 (45) | 17 (35) | |
| Sex | ||||
| M | 3 | 12 | 10 | NS |
| F | 7 | 10 | 7 | |
| Disease stage | ||||
| II-III | 3 | 6 | 6 | NS |
| IV | 7 | 16 | 11 | |
| Bone marrow involvement | ||||
| Yes | 7 | 16 | 9 | NS |
| No | 3 | 6 | 8 | |
| Extranodal sites involved | ||||
| Less than 2 | 8 | 20 | 13 | NS |
| 2 or more | 2 | 2 | 4 | |
| BCL2-JHrearrangement in peripheral blood | 8 | 12 | 11 | NS |
| BCL2-JH rearrangement in bone marrow | 7 | 12 | 11 | NS |
NS indicates nonsignificant.
Statistical comparisons of the 3 groups, of homozygousFCGR3A-158V patients versus FCGR3A-158F carriers, and of homozygous FCGR3A-158F patients versusFCGR3A-158V carriers.